PCSK9

Across TCGA pan-cancer cohorts, PCSK9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PCSK9 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PCSK9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCSK9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where PCSK9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.268	0.506	.004	36	view →
HNSC	DFS	Median	II,III,IV	0.989	0.904	.011	12	view →
LUAD	OS	Median	II,III,IV	0.782	1.000	.002	10	view →
GBM	DFS	Median	All	0.450	0.218	.005	7	view →
CCRCC	DFS	Median	III,IV	1.000	0.824	.025	3	view →
LSCC	DFS	Tertile	III,IV	1.000	0.451	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PCSK9–PDAC (DFS)

Open the PDAC breakdown →